TickerTalks
Browse all tickers →
TickerTalks›$EXOZ
EXEXOZ

eXoZymes, Inc.

$EXOZ·$66M·Biotechnology·Healthcare
$7.83+23.7%YTD-29.0%1Y-36.6%
Mentions · last 7 days
0
Price updated 31m ago
EXEXOZ
eXoZymes, Inc.$EXOZ
$7.83+23.70%0 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $EXOZ.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-6.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-362%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-221%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-0.28——
Q4 2025Mar 30, 2026$-0.32——
Q3 2025Nov 13, 2025$-0.27——
Q2 2025Aug 12, 2025$-0.28——

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.28$-1.6M
Q4 FY25$0———$-0.32$-2.0M
Q3 FY25$0———$-0.27$-1.9M
Q2 FY25$0———$-0.28$-1.6M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.12%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-18.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-30.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 2.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 9Korman Tyler PazChief Scientific Officer750 sh$8KSellApr 8Korman Tyler PazChief Scientific Officer750 sh$8K
+ 4 other (4 awards) in window

See when $EXOZ insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 178-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

eXoZymes (EXOZ) filed an 8-K on June 17, 2026 disclosing that underwriter MDB Capital exercised its partial overallotment option on the company's June 9, 2026 public offering, purchasing an additional 34,440 units (comprising 68,880 shares and 34,440 warrants). The original offering closed on June 9, 2026; this exercise formally closes the overallotment portion.

8-KMaterial agreementJun 88-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

eXoZymes (EXOZ) filed an 8-K on June 8, 2026 disclosing entry into an Underwriting Agreement with MDB Capital on June 5, 2026 for a public offering of approximately 592,270 shares and 292,135 warrants at $18.00 per unit, raising approximately $5.3 million gross (Item 1.01). MDB Capital also holds an overallotment option for 88,840 additional shares and 44,420 warrants. The company also furnished investor materials under Item 7.01.

424B5Prospectus supplement (offering)Jun 8424B5
AI summary

eXoZymes (EXOZ) filed a 424B5 final prospectus supplement for its public offering of 296,135 units at $18.00 each, with each unit comprising 2 shares and 1 warrant. Warrants are exercisable at $11.24 per share after a one-year lock-up anniversary and expire in five years; they are callable by the company under certain conditions. This small-cap offering raised approximately $5.3 million gross.

424B5Prospectus supplement (offering)Jun 4424B5
AI summary

eXoZymes (EXOZ) filed a preliminary 424B5 prospectus supplement on June 4, 2026 in connection with its proposed public offering, with offering amounts left blank pending final pricing. This is a routine pre-pricing placeholder filing.

424B5Prospectus supplement (offering)May 29424B5
AI summary

eXoZymes (EXOZ) filed a preliminary 424B5 prospectus supplement on May 29, 2026 with offering amounts left blank, representing an earlier iteration of its proposed public offering prior to the final prospectus filed June 4-8, 2026. This is a routine pre-pricing placeholder filing.

424B5Prospectus supplement (offering)Apr 9424B5
3New insider — initial holdingsApr 83
S-3Shelf registrationJan 16S-3
+ 7 other (4 routine 8-Ks · 1 10-Q · 1 10-K · 1 EFFECT) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

eXoZymes Inc. Announces Closing of $6 Million Public Offeringaccessnewswire.com·2d agoeXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrantsaccessnewswire.com·12d agoeXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Programaccessnewswire.com·44d agoeXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcastaccessnewswire.com·71d agoeXoZymes Provides Fourth Quarter and Full Year 2025 Updateaccessnewswire.com·80d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$QURE$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport